Spots Global Cancer Trial Database for ixazomib citrate
Every month we try and update this database with for ixazomib citrate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | NCT04047797 | Recurrent Mantl... Refractory Mant... | Ixazomib Ixazomib Citrat... Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | NCT02504359 | Plasma Cell Leu... Recurrent Plasm... | Allogeneic Hema... Carmustine Cytarabine Etoposide Ixazomib Citrat... Melphalan Methotrexate Peripheral Bloo... Quality-of-Life... Tacrolimus | 18 Years - 65 Years | OHSU Knight Cancer Institute | |
| A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | NCT02181413 | Multiple Myelom... Autologous Stem... | Ixazomib Citrat... Placebo | 18 Years - | Takeda | |
| Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment | NCT03770260 | Recurrent Multi... Refractory Mult... | Ixazomib Citrat... Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | NCT03399539 | Recurrent Plasm... t(11;14) | Dexamethasone Ixazomib Citrat... Laboratory Biom... Venetoclax | 18 Years - | Mayo Clinic | |
| Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | NCT03587662 | Metastatic Kidn... Metastatic Rena... SMARCB1 Negativ... Stage III Renal... Stage IV Renal ... | Doxorubicin Doxorubicin Hyd... Gemcitabine Gemcitabine Hyd... Ixazomib Ixazomib Citrat... | 12 Years - | M.D. Anderson Cancer Center | |
| Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | NCT02119468 | Refractory Plas... Recurrent Plasm... | ixazomib citrat... dexamethasone pomalidomide | 18 Years - | City of Hope Medical Center | |
| Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome | NCT02921893 | Plasmacytoma POEMS Syndrome | Dexamethasone Ixazomib Citrat... Lenalidomide Questionnaire A... | 18 Years - | Mayo Clinic | |
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | NCT02339922 | Chronic Lymphoc... Follicular Lymp... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Extra... Refractory Extr... Small Lymphocyt... Waldenstrom Mac... | Ixazomib Citrat... Laboratory Biom... Rituximab | 18 Years - | University of Washington | |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis | NCT04847453 | AL Amyloidosis | Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Dexamethasone Ixazomib Citrat... Magnetic Resona... Positron Emissi... Transabdominal ... Venetoclax X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) | |
| Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma | NCT00963820 | Multiple Myelom... | Ixazomib citrat... | 18 Years - | Takeda | |
| Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma | NCT03202628 | Recurrent Plasm... Refractory Plas... | Autologous Hema... Dexamethasone Ixazomib Citrat... Laboratory Biom... Pomalidomide | 18 Years - | Mayo Clinic | |
| Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | NCT02633059 | Loss of Chromos... Recurrent Plasm... | Dexamethasone Idasanutlin Ixazomib Citrat... Laboratory Biom... Pharmacological... | 18 Years - | Mayo Clinic | |
| Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib | NCT01415882 | Recurrent Plasm... Refractory Plas... | Cyclophosphamid... Daratumumab Dexamethasone Ixazomib Citrat... Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT02619682 | Plasma Cell Mye... Transplant-Rela... | Ixazomib Citrat... Laboratory Biom... Lenalidomide | 18 Years - | Fred Hutchinson Cancer Center | |
| A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | NCT02181413 | Multiple Myelom... Autologous Stem... | Ixazomib Citrat... Placebo | 18 Years - | Takeda | |
| Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT01718743 | Hematopoietic C... Plasma Cell Mye... | Ixazomib Citrat... Lenalidomide Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant | NCT02389517 | Plasma Cell Mye... Residual Diseas... | Ixazomib Citrat... Lenalidomide Dexamethasone | 18 Years - | University of Chicago | |
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | NCT02339922 | Chronic Lymphoc... Follicular Lymp... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Extra... Refractory Extr... Small Lymphocyt... Waldenstrom Mac... | Ixazomib Citrat... Laboratory Biom... Rituximab | 18 Years - | University of Washington | |
| Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma | NCT02542657 | Myeloma | Clarithromycin Dexamethasone Ixazomib Citrat... Pomalidomide | 18 Years - | University of California, Davis | |
| Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT03012880 | Plasma Cell Mye... | Daratumumab Dexamethasone Ixazomib Citrat... Laboratory Biom... Lenalidomide Questionnaire A... | 18 Years - | Mayo Clinic | |
| Trial of Ixazomib for Kaposi Sarcoma | NCT04305691 | Kaposi Sarcoma Skin | Ixazomib Citrat... Quality-of-Life... Questionnaire A... | 18 Years - | AIDS Malignancy Consortium | |
| Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | NCT02633059 | Loss of Chromos... Recurrent Plasm... | Dexamethasone Idasanutlin Ixazomib Citrat... Laboratory Biom... Pharmacological... | 18 Years - | Mayo Clinic | |
| Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia | NCT03506373 | Recurrent Walde... Refractory Wald... Waldenstrom Mac... | Ibrutinib Ixazomib Citrat... Laboratory Biom... Pharmacodynamic... Pharmacokinetic... | 18 Years - | Mayo Clinic | |
| Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT03012880 | Plasma Cell Mye... | Daratumumab Dexamethasone Ixazomib Citrat... Laboratory Biom... Lenalidomide Questionnaire A... | 18 Years - | Mayo Clinic | |
| Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial | NCT03941860 | Multiple Myelom... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Ixazomib Citrat... Lenalidomide Placebo Adminis... Positron Emissi... Quality-of-Life... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | NCT03399539 | Recurrent Plasm... t(11;14) | Dexamethasone Ixazomib Citrat... Laboratory Biom... Venetoclax | 18 Years - | Mayo Clinic | |
| Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma | NCT03856112 | Recurrent Plasm... Refractory Plas... t(11;14) Negati... | Dexamethasone Ixazomib Ixazomib Citrat... Venetoclax | 18 Years - | National Cancer Institute (NCI) | |
| Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery | NCT02420847 | Metastatic Urot... Transitional Ce... Unresectable Tr... | Doxorubicin Hyd... Gemcitabine Hyd... Ixazomib Citrat... | 18 Years - | M.D. Anderson Cancer Center | |
| Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT01718743 | Hematopoietic C... Plasma Cell Mye... | Ixazomib Citrat... Lenalidomide Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | NCT03506360 | Recurrent Plasm... | Dexamethasone Ixazomib Citrat... Laboratory Biom... Pembrolizumab | 18 Years - | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
